Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 2/20 | 0.34 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675910 | 0.87 | AURKA (0.41) | EGFRRETTSHRMAPTCHRNA3 | |
| SCHEMBL16682133 | 0.86 | EGFR (0.40) | WDR5EGFRRETCNR2CHRNA3 | |
| SCHEMBL16682118 | 0.84 | MAPK1 (0.42) | WDR5EGFRRETCNR2MAPT | |
| SCHEMBL16682108 | 0.79 | CYP2D6 (0.44) | WDR5POLBL3MBTL1 | |
| SCHEMBL16675946 | 0.74 | KDM4E (0.41) | TSHRMAPTMAPK1POLB | |
| SCHEMBL16675932 | 0.73 | EGFR (0.42) | EGFRRETCNR2CHRNA3 | |
| SCHEMBL16682107 | 0.72 | RET (0.37) | RET | |
| SCHEMBL16675905 | 0.71 | MAPK1 (0.45) | RETCHRNA3MAPK1 | |
| SCHEMBL16682128 | 0.70 | RET (0.39) | RET | |
| SCHEMBL16675900 | 0.70 | JAK3 (0.36) | RETMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | WDR5 1179/4885EGFR 4181/4885RET 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.